Oleksandr began writing for Market Realist in 2019. He's a founder of an investment research team focused on biotech companies that represents a lot of "shots" on goal. He focuses his trade strategy around "special situations" (such as catalysts, potential acquisitions, or spin-offs) and how to make money from those catalysts, as direct stock purchases, combined with option-based approaches for risk minimization.
Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.
